Biotech | January 07, 2022
Merck KGaA to acquire biopharma CDMO Exelead for $780 million
The transaction is expected to close in the first quarter of 2022
The transaction is expected to close in the first quarter of 2022
Hitz shall assume new role from January 17th, 2022
Acting as both a Dual Protease and TMPRSS2 Inhibitor, Pentarlandir is about to enter FDA Phase III trial¬
He has over 29 years of experience in the field of manufacturing, R&D, business and customer service management
Upon completion of successful human trials and regulatory approval, the joint venture's goal is to start delivering the second-generation vaccine in 2022 as soon as is practically possible
This next-generation CAR T construct was designed to improve the tolerability profile of conventional CD19 CAR Ts and developed in the laboratory of James N. Kochenderfer, M.D., at the National Cancer Institute, part of the NIH, the same laboratory that discovered axicabtagene ciloleucel
Healthy growth in domestic and emerging markets is expected to support revenue growth in the next few quarters
ASC10 is an oral direct-acting antiviral drug candidate targeting RNA dependent RNA polymerase (RdRp) to treat SARS-CoV-2 infection
The facility at the Andhra Pradesh Medtech Zone is expected to be completed by Dec 2022
Adbry is the first biologic launched by LEO Pharma in the United States and is expected to be available in pharmacies by February 2022
Subscribe To Our Newsletter & Stay Updated
